Transplantation in the era of the Covid-19 pandemic: How should transplant patients and programs be handled? #MMPMID32954602
NasrAllah MM; Osman NA; Elalfy M; Malvezzi P; Rostaing L
Rev Med Virol 2021[Jan]; 31 (1): 1-9 PMID32954602show ga
Due to the Covid-19 pandemic caused by SARS-CoV-2, transplant programs worldwide have been severely impacted with dwindling numbers of transplantations performed and a complete halt in several areas. In this review we examine whether SARS-CoV-2 infection presents differently in transplant recipients, whom and how we should test, how susceptible the transplant population is to overt infection and describe the range of outcomes. From retrieved published reports on SARS-CoV-2infections in 389solid organ transplant recipients reported in the literature, the overall mortality rate was 16.7% (n = 65); however for those with mild or moderate Covid-19 disease this was 2.9% and 2.3% respectively; conversely, for those with severe infection the mortality rate was 52.2%.We then address questions regarding halting transplantation programs during this pandemic, whether all human tissues being considered for transplantation are capable of transmitting the infection, and if we should alter immunosuppressive medications during the pandemic.
free
free
free
Rev+Med+Virol 2021 ; 31 (1): 1-9
